menu search

Omega therapeutics to present trial-in-progress poster for phase 1/2 mychelangelo™ i study at the american society of clinical oncology gastrointestinal cancers symposium

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion...

January 17, 2023, 7:00 am

Vulvovaginal candidiasis treatment market is likely to witness steady growth, anticipated to reach us$ 1607 million by 2033: future market insights, inc.

The vulvovaginal candidiasis treatment market is exploding, expected to skyrocket from its current US$1...

January 17, 2023, 5:30 am

Molecular partners initiates clinical study of trispecific candidate mp0533 for the treatment of acute myeloid leukemia

Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells...

January 16, 2023, 6:00 am

Amc networks and 2 other undervalued acquisition candidates with unexploited potential

AMC Network: strong content and underlying asset base. Totally unqualified board and management. HNI Corporation: Stock has gone nowhere in 25 years. ...

January 13, 2023, 3:42 pm

Fsd pharma plans buyback of up to 1.9 million shares to utilize cash reserves

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up ...

January 13, 2023, 9:46 am

Why oramed pharmaceuticals stock is crashing today

The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after ...

January 12, 2023, 11:50 am

Esg bonds could bounce back in 2023

In 2022, the widely observed Bloomberg US Aggregate Bond Index posted its worst annual showing since its inception in 1976. That is to say, plenty of ...

January 12, 2023, 9:33 am

: stripe reportedly slashes its internal valuation yet again, to $63 billion

Fintech startup and perennial IPO candidate Stripe Inc. has cut its internal valuation for a third time...

January 12, 2023, 4:20 am

American equity investment life: takeover candidate + 15% buyback yield

A significant increase in the company's net investment income resulted from a rise in interest rates. AEL announced a $400M increase to its share repu...

January 11, 2023, 2:39 pm

Pagegroup follows robert walters in highlighting dip in hiring

PageGroup PLC (LSE:PAGE) followed industry rival Robert Walters PLC in warning of a dip in hiring towards the end of 2022 as the economic slowdown loo...

January 11, 2023, 9:41 am

Vicor corp.: best near cap gain electrical infrastructure stock prospect

Our standard capital gain opportunity-seeking approach is to use the price-range forecasts implied by derivatives markets, and the market-making commu...

January 11, 2023, 5:19 am

Checkpoint therapeutics: an updated analysis

We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two in...

January 10, 2023, 1:40 pm

Is a short-squeeze in mullen automotive about to begin?

Mullen Automotive is a high-probability candidate for a short squeeze and the odds are rising that it w...

January 10, 2023, 12:42 pm

Abog approves aagl’s emigs training and testing program as option to meet surgical skills program standard

Dallas, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) — The American Board of Obstetrics and Gynecology (ABOG) has approved the American Association of Gyne...

January 9, 2023, 9:30 pm

Morgan stanley coo to retire at month's end

Morgan Stanley MS, +0.09% on Monday said that Chief Operating Officer Jonathan Pruzan would retire from his position on Jan. 31. Chief Executive James...

January 9, 2023, 5:18 pm

Nurix therapeutics advances promising targeted protein modulation pipeline and outlines 2023 strategic priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase pl...

January 9, 2023, 1:35 pm

Coherus agrees to acquire exclusive u.s. commercial rights to eylea® biosimilar fyb203 from klinge biopharma

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) �...

January 9, 2023, 1:20 pm

Aim immunotech broadens patent portfolio with new netherlands utility patent

AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a doubl...

January 9, 2023, 9:25 am

Context therapeutics announces manufacturing agreement with lonza for bispecific antibody targeting claudin 6 positive cancers

Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech...

January 9, 2023, 9:03 am

Nucana: pipeline and major gilead litigation progressing nicely

NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738,...

January 8, 2023, 4:30 am


Search within

Pages Search Results: